Skip to content

Author Correction: SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

Chimera readability score 74 out of 100, Expert reading level.

Correction to: Nature Medicine https://doi.org/10.1038/s41591-026-04452-0 published online 1 June 2026.
In the version of this article initially published, ref. 10 was cited twice and has been replaced by an omitted reference (Faivre E. J. et al. Cancer Res. https://doi.org/10.1158/1538-7445.AM2024-3148 (2024)), now cited as ref. 11 in the last paragraph of the introduction: “Preclinical studies in patient-derived xenograft models of SEZ6-positive SCLC demonstrated superior activity of ABBV-706 compared to ABBV-011 and standard-of-care chemotherapies10. Preliminary results from the ongoing first-in-human phase 1 trial (NCT05599984) to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity and antitumor activity of ABBV-706 in patients with R/R solid tumors (defined as those patients whose disease had progressed on or after treatment with standard of care), including patients with R/R SCLC, demonstrated that ABBV-706 monotherapy had a manageable safety profile and promising antitumor activity, with a confirmed ORR of 43.8% (60.9% in patients with R/R SCLC)11.” The reference has been updated in the HTML and PDF version of the article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/
About this article
Cite this article
Byers, L.A., Cho, B.C., Cooper, A.J. et al. Author Correction: SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial. Nat Med (2026). https://doi.org/10.1038/s41591-026-04544-x
Published:
Version of record:
DOI: https://doi.org/10.1038/s41591-026-04544-x

Sentinel — Human

Confidence

This text exhibits the precision and structural formality typical of human-edited academic publication data rather than generative synthetic content.

Signals Detected
low severity: Uniform rhythm and dense use of formal academic phrasing.
low severity: High structural coherence, typical of metadata or editorial review, lacking subjective flow.
low severity: Strict adherence to citation and attribution structure; no vague attribution markers present.
Human Indicators
The text functions as highly specific, formal editorial metadata (correction note) requiring precise, context-aware modification of academic citations.